Oncolytic Virus Therapy Market Size, Share & Trends Analysis Report By Product (Herpes Simplex Virus (HSV), Adenoviruses, Vaccinia Virus, Vesicular Stomatitis Virus, Newcastle Disease Virus), By Application, By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Oncolytic Virus Therapy Market Snapshot Chapter 4. Global Oncolytic Virus Therapy Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Penetration & Growth Prospect Mapping 4.6. Clinical Trial/Pipeline Analysis 4.7. Industry Analysis – Porter's Five Forces Analysis 4.8. Competitive Landscape & Market Share Analysis Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis 5.1. Product Type & Market Share, 2023 & 2031 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product: 5.2.1. HSV-based Oncolytic Viruses 5.2.2. Adenoviruses-based Oncolytic Viruses 5.2.3. Vaccinia Virus-based Oncolytic Viruses 5.2.4. Vesicular Stomatitis Virus-based Oncolytic Viruses 5.2.5. Newcastle Disease Virus-based Oncolytic Viruses Chapter 6. Oncolytic Virus Therapy Market Segmentation 2: Application Estimates & Trend Analysis 6.1. Application Analysis & Market Share, 2024-2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following Application: 6.2.1. Melanoma 6.2.2. Prostate Cancer 6.2.3. Breast Cancer 6.2.4. Ovarian Cancer 6.2.5. Others Chapter 7. Oncolytic Virus Therapy Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by product, 2021-2034 7.1.2. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by end-user, 2021-2034 7.1.3. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034 7.1.3.1. U.S. 7.1.3.2. Canada 7.2. Europe 7.2.1. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034 7.2.2. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034 7.2.3. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034 7.2.3.1. Germany 7.2.3.2. Poland 7.2.3.3. France 7.2.3.4. Italy 7.2.3.5. Spain 7.2.3.6. UK 7.2.3.7. Rest of Europe 7.3. Asia Pacific 7.3.1. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034 7.3.2. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034 7.3.3. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034 7.3.3.1. China 7.3.3.2. India 7.3.3.3. Japan 7.3.3.4. Australia 7.3.3.5. Rest of Asia Pacific 7.4. Rest of World 7.4.1. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034 7.4.2. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034 7.4.3. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034 7.4.3.1. Middle East 7.4.3.2. Africa 7.4.3.3. Latin America Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Provectus Biopharmaceuticals, Inc. 8.2.2. Takara Bio Inc. 8.2.3. SillaJen, Inc. 8.2.4. Oncorus, Inc. 8.2.5. Amgen 8.2.6. OncoMyx Therapeutics, Inc. 8.2.7. Replimune Inc. 8.2.8. Oncolytics Biotech 8.2.9. Vyriad, Inc. 8.2.10. Viralytics 8.2.11. Transgene SA 8.2.12. Oncolys BioPharma 8.2.13. Unleash Immuno Oncolytics, Inc. 8.2.14. Targovax 8.2.15. PsiOxus Therapeutics 8.2.16. Sorrento Therapeutics 8.2.17. Lokon Pharma AB 8.2.18. Genelux Corporation 8.2.19. TILT Biotherapeutics 8.2.20. Cold Genesys 8.2.21. Western Oncolytics